Pfizer Inc. $PFE Shares Sold by American Century Companies Inc.

American Century Companies Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 13.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,222,095 shares of the biopharmaceutical company’s stock after selling 334,926 shares during the period. American Century Companies Inc.’s holdings in Pfizer were worth $53,864,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Private Management Group Inc. increased its stake in Pfizer by 7.0% during the second quarter. Private Management Group Inc. now owns 81,773 shares of the biopharmaceutical company’s stock worth $1,982,000 after acquiring an additional 5,363 shares during the last quarter. Cowa LLC grew its holdings in shares of Pfizer by 12.6% during the 2nd quarter. Cowa LLC now owns 10,957 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 1,229 shares during the period. Richard W. Paul & Associates LLC increased its position in Pfizer by 21.9% during the 2nd quarter. Richard W. Paul & Associates LLC now owns 39,454 shares of the biopharmaceutical company’s stock worth $956,000 after purchasing an additional 7,100 shares in the last quarter. Cozad Asset Management Inc. raised its holdings in Pfizer by 4.1% in the second quarter. Cozad Asset Management Inc. now owns 38,086 shares of the biopharmaceutical company’s stock valued at $923,000 after buying an additional 1,509 shares during the period. Finally, Mufg Securities Americas Inc. lifted its position in Pfizer by 25.6% during the second quarter. Mufg Securities Americas Inc. now owns 126,004 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 25,689 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $25.72 on Friday. The stock’s 50 day moving average is $24.97 and its two-hundred day moving average is $24.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a market capitalization of $146.21 billion, a PE ratio of 13.68, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is presently 100.00%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.39.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.